Skip to main content
Pierluigi Porcu, MD, Oncology, Philadelphia, PA

Pierluigi Porcu MD

Oncology•Philadelphia, PA

Hematologic Oncology

Professor of Medical Oncology, Division Director of Hematologic Malignancies, and IRT Program Leader, Sidney Kimmel Cancer Center at Jefferson

Join to View Full Profile

  • 925 Chestnut StSte 420APhiladelphia, PA 19107

  • Phone+1 215-955-8874

  • Fax+1 215-955-2340

Dr. Porcu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Porcu's Full ProfileAlready have an account?

Summary

  • Dr. Pierluigi Porcu is a medical oncologist and physician scientist with a research focus in T-cell and NK-cell lymphoma and EBV-associated lymphomas. He is Division Director, Heme Malignancies and Hematopoietic Stem Cell transplantation and Program Leader, Immune Cell Regulation and Targeting at the Sidney Kimmel Cancer Center at Thomas Jefferson University, in Philadelphia, PA. He received his medical degree from University of Torino Faculty of Medicine and has been in academic practice in the US more than 20 years. He specializes in T-cell and NK-cell lymphomas and is an expert in the development of new therapies for blood cancers.

    • 2013 ASH - Interview with Pierluigi Porcu, MD - Former CLF Board Member

    Interview with with former CLF Board Member Pierluigi Porcu, MD, OSU Comprehensive Cancer Center.

    Meet Team Buckeye: PG Porcu, MD

    Associate Professor PG Porcu, MD, rides in Pelotonia for his patients. Hear why he thinks Pelotonia is such an important experience. 100% of all funds raised by

    2015 Detroit PEF - Q&A with Clinician Panel

    The question and answer session with our guest clinicians recorded at our Patient Educational Forum held in Detroit, Michigan.

    Cutaneous Lymphomas: Diagnosis and Staging

    Overview of how cutaneous lymphoma is diagnosed and classified; plus an explanation of staging.

    Dr. Porcu Discusses CTCL

    Pierluigi Porcu, MD, associate professor of internal medicine, Division of Hematology, Department of Internal Medicine, Wexner Medical Center, The Ohio State Un

    ASH 2013 - PierLuigi Porcu, M.D., and the Cutaneous Lymphoma Foundation.

    From ASH 2013, PierLuigi Porcu, M.D., discusses the Cutaneous Lymphoma Foundation's commitment to funding promising research with it's CLARIONS research awards

    Debate: What is the best approach for relapsed T cell lymphoma? - AlloSCT

    The continued evolution and refinement of strategies for disease diagnosis, risk assessment, therapeutic intervention and disease management have provided patie

Education & Training

  • Indiana University School of Medicine
    Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1996 - 1999
  • Indiana University School of Medicine
    Indiana University School of MedicineResidency, Internal Medicine, 1993 - 1996
  • University of Torino Faculty of Medicine
    University of Torino Faculty of MedicineClass of 1987

Certifications & Licensure

  • KY State Medical License
    KY State Medical License 2025 - 2027
  • PA State Medical License
    PA State Medical License 2016 - 2026
  • NJ State Medical License
    NJ State Medical License 2019 - 2025
  • OH State Medical License
    OH State Medical License 1999 - 2018

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
  • America's Top Doctors Castle Connolly, 2009-2014

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Quality of Life in Cutaneous T Cell Lymphoma Patients Treated with the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat: Results from MAVORIC  
    Pierluigi Porcu, MD, European Journal of Cancer
  • Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 Study  
    Michael S Khodadoust, Pierluigi Porcu, Francine Foss, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Steven M Horwitz, Elad Sharon, European Journal of Cancer
  • IPH4102 in relapsed/refractory Cutaneous T Cell Lymphoma (CTCL): Results of the First-in-Human Multicenter Phase 1 Study  
    Pierluigi Porcu, Basem William, Michael Khodadoust, European Journal of Cancer

Abstracts/Posters

  • Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia ...
    Pierluigi Porcu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Prospective Cohort of Black Patients with Mycosis Fungoides and S_zary Syndrome: Subset Analysis of the Mavoric Trial
    Pierluigi Porcu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • A phase Ib/II study of oral nanatinostat (N) and valganciclovir (VG) in subjects with Epstein-Barr virus (EBV)-associated lymphomas. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Efficacy of Mogamulizumab By Prior Systemic Therapy in Patients with Previously Treated Cutaneous T-Cell Lymphoma: Post Hoc Analysis from the Phase 3 Mavoric Study 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Long-Term Efficacy and Safety from the Copanlisib CHRONOS- Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

  • SOHO 2021: A Rapidly Changing Treatment Landscape in Classical Hodgkin’s LymphomaSeptember 2021
  • Quality of Life in Cutaneous T Cell Lymphoma Patients Treated with the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat: Results from MAVORICAugust 2018
  • IPH4102 in relapsed/refractory Cutaneous T Cell Lymphoma (CTCL): Results of the First-in-Human Multicenter Phase 1 StudyAugust 2018

Press Mentions

  • Innate Pharma Presents Lacutamab Improved Health-Related Quality of Life Data at ASH 2024 from TELLOMAK Phase 2 Study in Patients with Cutaneous T Cell Lymphoma
    Innate Pharma Presents Lacutamab Improved Health-Related Quality of Life Data at ASH 2024 from TELLOMAK Phase 2 Study in Patients with Cutaneous T Cell LymphomaDecember 9th, 2024
  • Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of Its Recent End of Phase 2 Meeting with the FDA
    Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of Its Recent End of Phase 2 Meeting with the FDADecember 7th, 2020
  • Viracta Announces Oral Presentation on Lead Program for EBV-Associated Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting
    Viracta Announces Oral Presentation on Lead Program for EBV-Associated Lymphomas at the 2019 American Society of Hematology (ASH) Annual MeetingNovember 6th, 2019

Grant Support

  • EBNA1 Inhibitor for Treatment of EBV-positive DLBCLWISTAR INSTITUTE2023–2028

Professional Memberships

Other Languages

  • Italian

External Links

  • LinkedInhttps://www.linkedin.com/in/pierluigi-porcu-661b9040?trk=nav_responsive_tab_profile_pic

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Pierluigi Porcu, Dr. Pierluigi Porcu, MD, Dr. P Porcu